Medical News / Reported from ASRS 2021 - Long-Term nAMD Patient Buy-In Is Still Lacking for Anti-VEGF Therapy

Real-world registry data presented this weekend at the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting this weekend by Theodore Leng, MD, MS, Associate Professor of Ophthalmology at Stanford University, showed patients with neovascular age-related macular degeneration (nAMD) are prone to discontinued treatment or lost to follow-up at 3 to 6 years of treatment. Source: MDMAG To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

MORE MEDICAL NEWS
The design of the American Society of Retina Specialists (ASRS) 2021 Scientific Meeting came to represent ... read more
Approximately 15 years into the era of anti-VEGF therapies for the treatment of age-related macular degeneration ... read more
Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends ... read more
In the coming weeks, the US Food and Drug Administration (FDA) will be considering the application ... read more